LON:SAR Sareum (SAR) Share Price, News & Analysis GBX 14.12 -0.88 (-5.87%) As of 05/30/2025 11:41 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Sareum Stock (LON:SAR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sareum alerts:Sign Up Key Stats Today's Range 14▼ 14.5050-Day Range 11.45▼ 20.5052-Week Range 11▼ 52.50Volume411,595 shsAverage Volume467,072 shsMarket Capitalization£17.64 millionP/E RatioN/ADividend Yield1.10%Price TargetN/AConsensus RatingN/A Company OverviewSareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.comRead More… Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Email Address SAR Stock News HeadlinesSareum Holdings Expands Share Capital Through Warrant ExerciseApril 24, 2025 | msn.comNetflix war film leaves viewers in tears as they label it 'absolute masterpiece'April 24, 2025 | msn.comHow I make 💰 trading from 135 countries I’ve traveled to 135 countries… In a new time zone almost every week… (Often 8… 12… 16 hours AHEAD of the United States) And yet I’ve made $7.9 million career profits… trading in the US markets?June 1, 2025 | Timothy Sykes (Ad)Sareum served notice on commercial licence for cancer treatmentDecember 31, 2024 | lse.co.ukSareum Holdings Refocuses Strategy After SRA737 Licensing TerminationDecember 31, 2024 | markets.businessinsider.comSareum annual loss widens as remains focused on autoimmune diseasesOctober 29, 2024 | lse.co.ukLONDON MARKET CLOSE: Stocks end upbeat ahead of UK budgetOctober 29, 2024 | lse.co.ukGiving room for cottage industry products to shineOctober 19, 2024 | msn.comSee More Headlines SAR Stock Analysis - Frequently Asked Questions How have SAR shares performed this year? Sareum's stock was trading at GBX 24.60 at the start of the year. Since then, SAR stock has decreased by 42.6% and is now trading at GBX 14.12. View the best growth stocks for 2025 here. How were Sareum's earnings last quarter? Sareum Holdings plc (LON:SAR) announced its quarterly earnings results on Tuesday, March, 25th. The company reported ($0.90) EPS for the quarter. How do I buy shares of Sareum? Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Summit Therapeutics (SMMT). Company Calendar Last Earnings3/25/2025Today6/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryFinancial Services Current SymbolLON:SAR CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700FaxN/AEmployees3,211Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (4.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.28 million Net MarginsN/A Pretax MarginN/A Return on Equity-270.25% Return on Assets-113.80% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio10.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.25 per share Price / Cash Flow11.32 Book ValueGBX 2.61 per share Price / Book5.41Miscellaneous Outstanding Shares124,928,001Free FloatN/AMarket Cap£17.64 million OptionableNot Optionable Beta-1.08 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (LON:SAR) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Sareum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.